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Introduction and Aim:  
Carriage of rs738409:G in PNPLA3 plays an important role in determining the risk for developing 
alcohol-related cirrhosis and influences several important aspects of disease progression and 
outcome. In patients with severe alcoholic hepatitis homozygosity for rs738409:G in PNPLA3 confers 
significant additional risk of mortality. The aim of this study was to determine whether carriage of 
rs738409:G is associated with the histological severity of alcoholic hepatitis at presentation. 
Material and Methods:  
The study population comprised participants in the Steroids or Pentoxifylline for Severe Alcoholic 
Hepatitis (STOPAH) trial with available DNA in whom liver histology of sufficient quality and 
adequately timed with respect to the start of treatment was available. The liver biopsy material was 
assessed by two histopathologists using the alcoholic hepatitis histological scoring system. Images 
were also digitally scanned and the collagen (CPA) and fat proportionate areas (FPA) quantified. 
Baseline, pretreatment serum levels of the M30 and M65 subtypes of cytokeratin-18 were measured 
by ELISA. Associations with the rs738409 genotype were examined.  
Results:  
A total of 129 participants (men: 89 [69%]; mean age: 49 [IQR 42 – 56]) were included, median time 
to biopsy was 4 days from treatment start. There was a significant positive association between 
carriage of rs738409:G and severe hepatic inflammation (CC: 4/53 (7.5%); CG 16/50 (32%); 4/12 (33%), 
p = 0.003) but not severe hepatocyte ballooning (CC: 29/53 (55%), CG: 31/50 (62%), GG: 5/12 (42%), 
p = 0.43). Severe inflammation and ballooning were significantly positively associated with serum 
levels of both CK18- M30 (p < 0.01) and CK18-M65 (p < 0.01). Carriage of rs738409:G was associated 
with higher serum levels of both CK18- M30 (p = 0.01) and CK18-M65 (p = 0.07). Carriage of this risk 
allele was associated with greater CPA (CC: 30% [22–36%], CG: 33%[24–38%], GG: 42%[29–48%], p = 
0.01) but lower FPA [CC: 13.6% [10.0–21.5%], CG: 11.5% [8.0–17.5%], GG:8.5% [6.4–- 14.1%], p = 0.02). 
Conclusions:  
In patients presenting with alcoholic hepatitis carriage of rs738409:G in PNPLA3 is associated with 
more extensive hepatic fibrosis, more severe hepatic inflammation and increased serum markers of 
hepatocyte death. These findings may explain, in part, the higher medium-term mortality seen in 
carriers of this risk allele. 
